152 related articles for article (PubMed ID: 38777312)
1. Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease.
Sharma S; Kumar S; Tomar MS; Chauhan D; Kulkarni C; Rajput S; Sadhukhan S; Porwal K; Guha R; Shrivastava A; Gayen JR; Kumar N; Chattopadhyay N
Bone; 2024 Aug; 185():117126. PubMed ID: 38777312
[TBL] [Abstract][Full Text] [Related]
2. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
[TBL] [Abstract][Full Text] [Related]
3. Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.
Yu L; Tomlinson JE; Alexander ST; Hensley K; Han CY; Dwyer D; Stolina M; Dean C; Goodman WG; Richards WG; Li X
Calcif Tissue Int; 2017 Dec; 101(6):641-653. PubMed ID: 29038882
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of calcitriol and calcimimetic on bone health in renal insufficiency.
Díaz-Tocados JM; Rodríguez-Ortiz ME; Herencia C; López-Baltanás R; Jurado-Montoya D; García-Saez RM; Valdés-Díaz K; Martínez-Moreno JM; Santamaría R; Pendón-Ruiz de Mier MV; Rodelo-Haad C; Frazão JM; Felsenfeld AJ; Rodríguez M; Almadén Y; Muñoz-Castañeda JR
FASEB J; 2024 Jun; 38(11):e23726. PubMed ID: 38847773
[TBL] [Abstract][Full Text] [Related]
5. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
6. Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study.
Mima A; Tansho K; Nagahara D; Watase K
J Int Med Res; 2018 Nov; 46(11):4578-4585. PubMed ID: 30027791
[TBL] [Abstract][Full Text] [Related]
7. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Bernardor J; De Mul A; Bacchetta J; Schmitt CP
Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
[TBL] [Abstract][Full Text] [Related]
8. Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats.
Hasegawa T; Tokunaga S; Yamamoto T; Sakai M; Hongo H; Kawata T; Amizuka N
Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36718587
[TBL] [Abstract][Full Text] [Related]
9. Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Sato H; Goto M; Nishimura G; Morimoto N; Tokushima H; Horii Y; Takahashi N
Bone; 2023 Feb; 167():116613. PubMed ID: 36395959
[TBL] [Abstract][Full Text] [Related]
10. A rat model of SHPT with bone abnormalities in CKD induced by adenine and a high phosphorus diet.
Ni LH; Tang RN; Lv LL; Wu M; Wang B; Wang FM; Ni HF; Song KY; Wang LT; Meng-Zuo ; Chen Q; Liu BC
Biochem Biophys Res Commun; 2018 Apr; 498(3):654-659. PubMed ID: 29545182
[TBL] [Abstract][Full Text] [Related]
11. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.
Sakai M; Tokunaga S; Kawai M; Murai M; Kobayashi M; Kitayama T; Saeki S; Kawata T
PLoS One; 2020; 15(4):e0232428. PubMed ID: 32343734
[TBL] [Abstract][Full Text] [Related]
12. Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study.
Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T
Clin Ther; 2018 Dec; 40(12):2099-2111. PubMed ID: 30473399
[TBL] [Abstract][Full Text] [Related]
13. Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control.
Massy ZA; Hénaut L; Larsson TE; Vervloet MG
Semin Nephrol; 2014 Nov; 34(6):648-59. PubMed ID: 25498383
[TBL] [Abstract][Full Text] [Related]
14. Calcimimetics Alter Periosteal and Perilacunar Bone Matrix Composition and Material Properties in Early Chronic Kidney Disease.
Damrath JG; Moe SM; Wallace JM
J Bone Miner Res; 2022 Jul; 37(7):1297-1306. PubMed ID: 35593150
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of Parsabiv
Harada K; Fujioka A; Konno M; Inoue A; Yamada H; Hirota Y
Eur J Pharmacol; 2019 Jan; 842():139-145. PubMed ID: 30342948
[TBL] [Abstract][Full Text] [Related]
16. Current therapeutic options for the treatment of secondary hyperparathyroidism in end-stage renal disease patients treated with hemodialysis: a 12-month comparative study.
Dudar I; Shifris I; Dudar S; Kulish V
Pol Merkur Lekarski; 2022 Oct; 50(299):294-298. PubMed ID: 36283011
[TBL] [Abstract][Full Text] [Related]
17. Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease.
Swallow EA; Metzger CE; Newman CL; Chen NX; Moe SM; Allen MR
Bone; 2022 Apr; 157():116340. PubMed ID: 35085840
[TBL] [Abstract][Full Text] [Related]
18. Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.
Ureña Torres PA; Bover J; Cohen-Solal M
Drugs Today (Barc); 2017 Sep; 53(9):489-500. PubMed ID: 29238762
[TBL] [Abstract][Full Text] [Related]
19. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients.
Fukagawa M; Yokoyama K; Shigematsu T; Akiba T; Fujii A; Kuramoto T; Odani M; Akizawa T;
Nephrol Dial Transplant; 2017 Oct; 32(10):1723-1730. PubMed ID: 28057872
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review and Meta-analysis of Efficacy and Safety of Calcimimetic Agents in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
Liu Y; Yang Q; Chen G; Zhou T
Curr Pharm Des; 2022; 28(40):3289-3304. PubMed ID: 36305135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]